NasdaqGM:ATAIPharmaceuticals
Why AtaiBeckley (ATAI) Is Down 7.3% After FDA Backs BPL-003 Phase 3 Depression Trials
AtaiBeckley Inc. recently reported a successful End-of-Phase 2 meeting with the FDA, securing agency support to advance its proprietary intranasal mebufotenin candidate BPL-003 into two Phase 3 ReConnection trials for adults with treatment-resistant depression, while separately releasing encouraging first-in-patient Phase 2a data for EMP-01 in social anxiety disorder and appointing industry veteran Michael Faerm as Chief Financial Officer.
The FDA’s backing of the BPL-003 pivotal program,...